Tadalafil
Product Images NDC 71335-1400

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71335-1400). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713351400)

Label for Tadalafil 10mg Tablet, packaged by Bryant Ranch Prepack in Burbank, CA. The label indicates it is comparable to Cialis 10mg Tablet by Amneal Pharmaceuticals Pvt. Ltd. The package contains 30 tablets with an NDC of 71335-1400-1. Storage instructions include keeping at room temperature 20°-25°C (68°-77°F) and keeping all drugs out of reach of children. The label also includes a barcode and lot number.*

FDA Label Image

10 (Tadalafil Tablets Usp 1)

Chemical structure diagram of the active ingredient Tadalafil, showing its detailed molecular arrangement with multiple rings and functional groups.*

FDA Label Image

10 (Tadalafil Tablets Usp 2)

Four line graphs showing the difference in blood pressure measurements (Tadalafil minus Placebo) over time (hours) for standing and supine systolic and diastolic blood pressure. Each graph has error bars representing variability. The x-axis indicates time from 0 to 96 hours, and the y-axis shows the difference in mmHg from -10 to 6.*

FDA Label Image

10 (Tadalafil Tablets Usp 3)

Line graphs depicting changes in standing and supine systolic blood pressure over 24 hours post-dose. Two treatments are compared: Tadalafil 20 mg combined with doxazosin 8 mg, and a placebo with doxazosin 8 mg. The vertical axes display blood pressure changes in mmHg, while the horizontal axes represent time in hours after dosing.*

FDA Label Image

10 (Tadalafil Tablets Usp 4)

A line graph showing changes in systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo combined with 8 mg once daily doxazosin. Four groups are compared based on timing and treatment: 20 mg tadalafil at 08:00, placebo at 08:00, 20 mg tadalafil at 20:00, and placebo at 20:00. The y-axis ranges from -20 to 20 mmHg and the x-axis represents time in hours after administration.*

FDA Label Image

10 (Tadalafil Tablets Usp 5)

A pharmacokinetic curve showing plasma tadalafil concentration (mcg/L) over time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following 5 consecutive days of administration. The graph includes error bars representing variability in concentration measurements.*

FDA Label Image

10 (Tadalafil Tablets Usp 6)

A line graph comparing change from baseline in IPSS total score over 12 weeks of treatment between Tadalafil 5 mg and placebo groups. The x-axis represents duration of treatment in weeks, and the y-axis shows change in score. Tadalafil shows a greater decrease in score over time compared to placebo, with statistical significance indicated at week 12 (p<0.01).*

FDA Label Image

10 (Tadalafil Tablets Usp 7)

A line chart comparing change from baseline in IPSS total score over 12 weeks between Tadalafil 5 mg and placebo groups. The x-axis represents duration of treatment in weeks, and the y-axis shows change in score. Tadalafil shows a greater reduction compared to placebo with statistically significant differences at weeks 4 and 12 noted.*

FDA Label Image

10 (Tadalafil Tablets Usp 8)

A line graph depicting the least squares mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride (solid line with diamond markers) versus Placebo/Finasteride (dashed line with circle markers). The graph shows greater reduction in the measured outcome for Tadalafil/Finasteride across the time points 0, 4, 12, and 26 weeks, with statistical significance indicated at weeks 4, 12, and 26.*

FDA Label Image

10 (Tadalafil Tablets Usp 9)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks of treatment for Tadalafil 5 mg versus placebo. The x-axis shows duration of treatment in weeks (0, 2, 4, 8, 12), and the y-axis displays the change in score. Tadalafil shows a greater decrease in IPSS Total Score compared to placebo over time, with statistical significance indicated at 12 weeks.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.